To Investigate the Relationship Between the Viscoelastic Properties of the Zona Pellucida of Human Oocyte and the Blastocyst Utilization Rate

Launched by INTI LABS · Feb 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the physical properties of the zona pellucida, the protective layer surrounding human eggs (oocytes), can help predict the quality of the eggs and the success of in vitro fertilization (IVF). Researchers are using a special, safe device called OPAL X1 to measure these properties without harming the eggs. By analyzing the data, they hope to determine which eggs are more likely to lead to successful fertilization and healthy embryos, ultimately improving treatment strategies for women undergoing IVF.

To participate in this trial, women must be aged 38 or younger, have a certain level of a hormone called anti-Müllerian hormone (AMH), and have at least 10 eggs collected for IVF. It's important that participants do not have certain medical conditions, such as untreated uterine abnormalities or an unhealthy body weight. Those who join the study can expect to have their eggs assessed for quality using the OPAL X1 device, which could provide useful information for their IVF treatment and increase the chances of a successful pregnancy.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Women who have started the in vitro fertilization (IVF) treatment and related examinations.
• • 2. Female participants aged ≤38 years with an anti-Müllerian hormone (AMH) concentration greater than 1.1 ng/mL and a collected oocyte count of more than 10.
• • 3. Participants who consent to undergoing IVF with intracytoplasmic sperm injection (ICSI) and time-lapse embryo culture.
• Exclusion Criteria:
• • 1. Women diagnosed with untreated uterine abnormalities as assessed by a physician.
• • 2. Participants with a body mass index (BMI) outside the range of 18.5-30 kg/m\^2.
• • 3. Patients undergoing IVF using sperm retrieved through surgical extraction.
• • 4. Patients undergoing IVF using donated oocytes or donated sperm.